Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Agreed. This is a game changer.
Yes, it doesn't matter whether the patients get really sick and develop acute lung injury and acute respiratory distress syndrome at first, or later after a re-activation occurs. The fact is that data is emerging that shows our body isn't developing a good immune response and that's concerning. Ifenprodil doesn't care about the immune response though. Ifenprodil is an NMDA-antagonist. It plays a role in decreasing the amount of neuron (nerves) hyper-excitability, it also modulates the pulmonary (lung) capillary (small blood vessel) ability to leak out protein and fluid (the stuff that causes the acute respiratory distress syndrome). As I mentioned, that leaking can happen during the initial period of infection or later after re-activation. Ifenprodil will be helpful at either time point.
They are going to announce approval of their South Korea trial this week. The stock won't be hanging out in the 20's for long.
Some Science
1. Pre-clinical research: check out your BioPub interviews. These are quick and explain Algernon's plan of action in a concise and clear way. They make the science easy to understand. They discuss the positive data from animal studies that shows our drugs generated positive signal and treated the disease of interest. One aspect of our drug pipeline is for idiopathic pulmonary fibrosis and chronic cough. Our lead outperforms the best drug big pharma has to offer.
Called it.
AHAHA!
I laughed out loud at this. Sadly, very true in so many ways.
Invest in science. It pays off.
Health Canada is interested. Ethics is submitted for chronic cough in Australia. Ethics is submitted in South Korea for COVID-19. Ethics going in soon for Australia for COVID-19. FDA registered trial on clinicaltrials.gov in the USA.
These guys aren't playing around. Mark Williams is going BEAST MODE.
I've literally never seen this kind of productivity. These ethics submissions are a HUGGGGGGGGGGGGE amount of work.
No problem Shell3. That's why I post my DD. The science is fact and everyone should have access to it to make informed decisions. I'm in heavy because I believe in the science.
We will see COVID trial get submitted this week.
Invest in the science. See my post that I have replied to here.
Yes sir!
Let's summarize the last few months, scientifically.
There's been a lot of talk lately about warrants and share price and such. However, what matters is how is this company going to boost it's share price and make us money. The answer, is scientific data. That's all that matters. That's what is going to score Algernon the multi-million if not billions in licensing fees or a buy-out.
So, let the science do the talking... and don't forget... they also have a patent on the long forgotten sister drug of ifenprodil, which performed just as well in their animal model. They patented that one too don't forget. I'm not going to re-post the news release, it's freely available on their website. Do your DD.
Ok enough blabbing, here's the science:
1. Pre-clinical research: BioPub interviews are the best thing for those who are new here to watch. They discuss the positive data from animal studies that shows our drugs generated positive signal and treated the disease of interest. One aspect of our drug pipeline is for idiopathic pulmonary fibrosis and chronic cough. Our lead outperforms the best drug big pharma has to offer. Nothing catches BigPharma's attention like a small company that has a more effective drug. Billions of $ of profit are on the line.
I'm actually kind of happy to see that someone read and appreciated my explanation of the scientific reasoning for why we are all going to make a lot of money off this treatment for lung disease...
TRIAL REGISTRATION!!!
Now we have FDA registration for ifenprodil testing in USA AND WE HAVE THE FOLLOWING:
HARD SCIENCE
Furthermore, for those interested in the science:
Coronavirus infection induces increased production of proinflammatory cytokines and neuronal degeneration as a consequence of glutamate excitotoxicity. In physiological conditions, glutamate is mainly synthesized by neurons and released in the synaptic cleft as the primary excitatory neurotransmitter of the CNS that activates the ligand-dependant receptor AMPAr, which allows the entry of sodium ions and the passage of the nerve impulse in the post-synaptic neuron, leading to activation of the NMDA receptor (N-methyl-D-aspartate receptor) that allows the entry of calcium ions. During infection of neurons by coronavirus, microglial cells detect the presence of virus and produce pro-inflammatory cytokines (TNF-alpha, IL-1 beta and IL-6) that down-regulate the astrocytic receptor GLT-1 (glutamate transporter 1) and prevent the efficient recapture of glutamate. This situation disturbs the regulation of glutamate homeostasis and theexcess of this neurotransmitter in the synaptic cleft leads to excitotoxicity associated with a massive entry of calcium which eventually leads to degeneration of and death of neuronal cells.
This is why NMDA ANTAGONIST IFENPRODIL is going to be helpful for saving neurons!
Holy crap their on fire.
Their productivity is remarkable. Seriously, these huge ethics applications take forever. This is an impressive pace.
Ifenprodil works on the NMDA receptor on neurons.
NMDA receptor
And SARS-COV-2 aka COVID-19 hurts the neurons:
Neuroinvasive potential of COVID-19 may hurt respiratory drive and cause respiratory failure
This study shows NMDA receptor plays a role in neuronal cell death:
Review of how NMDA involved in neuronal cell death
So Ifenprodil may actually help keep the neurons alive. It might help people from failing to breath.
I mean just look at this study hot off the press that shows neurologic issues that COVID-19 causes:
Neurologic manifestations of COVID-19
BOOOM
My thoughts:
Your timeline is reasonable. See point 3 below for the key step which must be considered for us to determine timelines for scientific trials.
For those who don't work in science-related industry, here are a few key steps required to get the ball rolling and get some scientific data aka the stuff that is going to send this stock to the moon... and I am not going to waste a lot of time repeating what's spelled out very clearly in the BioPub interview Algernon did because that was very clear and anyone investing here should have watched that.
1. Pre-clinical research: As stated in BioPub interview, having data in animal studies that shows your drug has therapeutic efficacy (aka it actually treats the disease of interest). We have this done. As Smoki pointed out... one aspect of our drug pipeline is for idiopathic pulmonary fibrosis and chronic cough... and our lead outperforms the best drug big pharma has... you better not kid yourself, big pharma is watching, they definitely saw the headlines... they always watch for competition...
FDA registration....
In my opinion, the single most important variable (aside from having patent protected drugs) in determining whether share price shoots to the moon for small pharma companies, is having registered trials that can generate REAL SCIENTIFIC DATA. We are now registered to run a trial to gain some prelim data through the US FDA. Next, we will run NOVOTECH (registered CRO) sponsored COVID trials in Asia and South Korea. Then we will run IPF and chronic cough trials via Novotech.
Can't argue with science
Bright like a diamond is right.
The future is bright
WOW THIS IS HUGEEEEEEEEEE. Nice find man... seriously...
THIS IS THE REAL DEAL. FDA on board! Here we go.
Nice post. Speaking on behalf of all, we appreciate the hard work you put into providing DD and explaining company dynamics.
Yes, we are. It's just a matter of time. As soon as the news outlets pick this up and people become aware of their opportunity to grab this golden ticket.
This is why I go to the science. Hard facts.
This company has the science behind them. And the patents. And a CRO who's got a near quarter million invested in them.
Those who are new to the board should do some DD, although a ton has been posted here in the last month, and figure out the intrinsic value of the company:
I would say watch the BioPub vid, but here are some thoughts off the top of my head:
There's hundreds of millions in saved costs by repurposing a safe drug.
We have animal data showing our drug outperforms the big pharma industry leader for more than one disease process.
We have a internationally recognized CRO that is not only going to run our trials, but have skin in the game and have invested 200k of their own money.
We are getting steady, clear, transparent news releases from our mad scientist.
Drug is legal in the country we are testing.
Global market is DESPERATE for a solution to acute lung injury.
The list goes on.
With the current listing/exchange we are on, there will be day traders and low volume will lead to significant fluctuations in share price... the volatility will shake some out. Those acquiring and putting down big bets are not worried they will pick them up. The important thing to remember here is that the timeline for pharmaceutical companies working on drug trials is not days or weeks. The short term really doesn't matter. Sure coronavirus might help speed up the trial process but we are still talking months. Buy, hold, and have some patience. If we get positive data in the next couple months from prelim coronavirus trials, this thing is going to shoot to several dollars if not more because of the global need. Who wouldn't want to pick up a penny stock with chances like that. When the trial data release is nearing, share price will creep because people will want in. Happens with pharma all the time.
Provide a reference for your claim.
Not trying to be rude but you don't even know that they are RNA viruses, not DNA viruses... so don't lecture on mutations.
Ifenprodil for influenza, pulmonary fibrosis, and coronavirus:
It may be the solution to these respiratory disease because there's great overlap in the pathology and mechanism of illness. Global systemic inflammatory response makes the patient's lungs more susceptible to leaky blood vessels (capillaries) which leads to edema (fluid) leaking into the lungs. The lungs are like bags of air, but become filled with fluid. They get wet and heavy, and the patients oxygen goes down. This causes injury to the lungs. They start to die. This is Acute Respiratory Distress Syndrome and Acute Lung Injury. That's when a ventilator has a hard time saving them.
To quote Algernon from there recent news, it is clear why we are going after multiple different disease (coronavirus, pulmonary fibrosis, etc). There is overlap:
Mutates quicker than does the "flu" aka influenza
Not true.
The virus is just as likely to mutate into a more pathogenic (virulent) damaging form, as it is to mutate into a more benign (less virulent) form.
NEWS! A Summary:
Thanks for the DD. You hit the nail on the head! Acute lung injury and ARDS have been a source of serious morbidity and mortality in the USA and around the globe. It is also associated with influenza. Influenza is more common than coronavirus (COVID-19) and the number of people who could use this therapy as a treatment after developing acute lung injury/ARDS secondary to influenza is staggering.
We are finding out quickly that Ifenprodil holds MASSIVE potential.
It is my belief we will also have a trial coming in hot for acute lung injury/ARDS caused by influenza. Maybe after the coronavirus trial. Here's why:
The global community needs a treatment.
A vaccine will help slow the spread but there will always be a need for a treatment to decrease the severity of the lung disease caused by coronavirus. A vaccine will help slow the number of new cases but there will always be severe cases that result in patients ending up on ventilators with bad Acute Respiratory Distress Syndrome and Acute Lung Injury. Those patients may benefit from our therapy.
Algernon is stepping up to the global stage in a time of need. This is bigger than a penny stock. This is about helping the global community. Kudos to them for working hard every day to move this forward and help those in need.
Actually,
Coronaviruses do mutate. It's an excellent point he's made. The fact the virus mutates is why the global scientific community is so panicked. Because it makes vaccines less effective.
Globally, this is very concerning. The virus might fade in the summer and come back just as strong in the fall/winter. It might do that twice per year for the rest of time.
If so, we are f***** as a society. But we shouldn't get to far ahead of ourselves. It's early days.
The only bright side to this is that certain treatments might help decrease the intensity of the illness and keep people alive. Ifenprodil is one. God bless you all as we prepare for take off because the market is going to eat this up. So is big pharma. Our global community is in dire need of a treatment that helps decrease the severity of the illness.
The best part...
The fact that every single release represented a thoughtful, tangible step toward diversifying the drug pipeline and clinical trials roster. Each release represented a legitimate step forward, the right direction.
Good times.
Stockhouse Features
Playing with the big kids
YAHOO NEWS
Financial Buzz NEWS
Foreign News
Once international sources get wind of this company, we will never see these share prices again. It's a ticking time bomb.
Some DD.
For those who missed it this weekend. Check out my DD/previous post:
Danny you highlight an important point. The US Department of Energy used there supercomputer to identify compounds that could help decrease coronavirus infectivity. That had nothing to do with Algernon. Ifenprodil was identified independently. Also agree with the comments about the choice of top tier CRO to run their trials.
They specifically released a news article saying they contacted them...
Do some reading mate, coming to this board can't replace doing your own basic research.
To date,
there is no cure. That is correct. There won't be a cure, the virus undergoes mutations to rapidly. However, there are pharmaceutical companies doing research on therapies that can decrease the amount of injury people suffer. Algernon is testign a safe, known therapy to help decrease the injury to human lungs, and to hopefully save lives.
If you are interested in some Monday reading, see my previous post on how our drug Ifenprodil may decrease infectivity of coronavirus.
You are correct.
There are very few companies developing therapies. Many developing vaccines but there are almost none developing treatments for the lung injury. The market is our's for the taking.
We are scaling up drug manufacturing to prepare for our trial. There are very few others ongoing. We are definitely out of the gate in the lead. There is room for multiple treatments in this field. There's not just going to be one winner.